A Phase I, Dose Escalation Study of BNC101 (Anti-LGR5 Humanized Monoclonal Antibody) in Patients With Metastatic Colorectal Cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs BNC 101 (Primary)
- Indications Colon cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Bionomics
- 20 Apr 2016 Status changed from not yet recruiting to recruiting.
- 31 Aug 2015 According to Bionomics media release, IND for this trial has passed review by US FDA and the trial is expected to initiate before the end of 2015.
- 31 Aug 2015 According to Bionomics media release, status changed from planning to not yet recruiting.